发明名称 Hepatitis C virus inhibitors
摘要 The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
申请公布号 US9018390(B2) 申请公布日期 2015.04.28
申请号 US201313919027 申请日期 2013.06.17
申请人 Bristol-Myers Squibb Company 发明人 Bachand Carol;Belema Makonen;Deon Daniel H.;Good Andrew C.;Goodrich Jason;James Clint A.;Lavoie Rico;Lopez Omar D.;Martel Alain;Meanwell Nicholas A.;Nguyen Van N.;Romine Jeffrey Lee;Ruediger Edward H.;Snyder Lawrence B.;St. Laurent Denis R.;Yang Fukang;Langley David R.;Hamann Lawrence G.
分类号 C07D233/00;C07D233/02;A01N43/50;A61K31/415;C07D403/14;A61K31/4178;A61K31/4545;A61K31/5377;A61K31/695;A61K45/06;C07D401/14;C07F7/10 主分类号 C07D233/00
代理机构 代理人 Mingo Pamela A.
主权项 1. A compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein u and v are independently 0, 1, 2, or 3; one of A and B is phenyl and the other is pyridine; each Rl and R2 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, —NRaRb, (NRaRb)alkyl, and (NRaRb)carbonyl; R3 and R4 are each independently selected from hydrogen, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, haloalkyl, (NRaRb)carbonyl, and trialkylsilylalkoxyalkyl; R5 and R6 are each independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, haloalkyl, and (NRaRb)alkyl; or, R5 and R6, together with the carbon atom to which they are attached, form a five or six membered saturated ring optionally containing one or two heteroatoms selected from NRz, O, and S; wherein Rz is selected from hydrogen and alkyl; R7 is selected from hydrogen, R9—C(O)—, and R9—C(S)—; R8 is selected from hydrogen and alkyl; R9 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonylalkyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, (cycloalkyl)alkenyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, haloalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, hydroxyalkyl, —NRcRd, (NRcRd)alkenyl, (NRcRd)alkyl, and (NRcRd)carbonyl; R10 is selected from  wherein R11 and R12 are each independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, haloalkyl, and (NRaRb)alkyl; or, R11 and R12, together with the carbon atom to which they are attached, form a five or six membered saturated ring optionally containing one or two heteroatoms selected from NRz, O, and S;wherein Rz is selected from hydrogen and alkyl; R13 is selected from hydrogen and alkyl; R14 is selected from hydrogen, R15—C(O)—, and R15—C(S)—; R15 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonylalkyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, (cycloalkyl)alkenyl, (cycloalkyl)alkyl, cycloalkyloxyalkyl, haloalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, hydroxyalkyl, —NRcRd, (NRcRd)alkenyl, (NRcRd)alkyl, and (NRcRd)carbonyl; m is 0, 1, or 2; n is 0, 1, 2, 3, or 4; X is selected from O, S, S(O), SO2, CH2, CHR16, and C(R16)2; provided that when m is 0, X is selected from CH2, CHR16, and C(R16)2; each R16 is independently selected from alkoxy, alkyl, aryl, halo, haloalkyl, hydroxy, and —NRaRb, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups.
地址 Princeton NJ US